Pharmacokinetics of Py-Im polyamides depend on architecture: cyclic versus linear.
about
Antitumor activity of a pyrrole-imidazole polyamideBinding studies of a large antiviral polyamide to a natural HPV sequence.A C-14 labeled Py-Im polyamide localizes to a subcutaneous prostate cancer tumor.Tumor xenograft uptake of a pyrrole-imidazole (Py-Im) polyamide varies as a function of cell line grafted.Synthesis of cyclic Py-Im polyamide libraries.Fluorescent probes for nucleic Acid visualization in fixed and live cells.Polyamide fluorescent probes for visualization of repeated DNA sequences in living cells.Characterization and solubilization of pyrrole-imidazole polyamide aggregatesSingle-dose pharmacokinetic and toxicity analysis of pyrrole-imidazole polyamides in mice.Gene expression changes in a tumor xenograft by a pyrrole-imidazole polyamide.Correlation of local effects of DNA sequence and position of β-alanine inserts with polyamide-DNA complex binding affinities and kinetics.Activity of a Py-Im polyamide targeted to the estrogen response element.Animal toxicity of hairpin pyrrole-imidazole polyamides varies with the turn unit.Androgen receptor antagonism by divalent ethisterone conjugates in castrate-resistant prostate cancer cells.Binding to the DNA minor groove by heterocyclic dications: from AT-specific monomers to GC recognition with dimers.An HRE-Binding Py-Im Polyamide Impairs Hypoxic Signaling in Tumors.Pyrrole-imidazole polyamide targeted to break fusion sites in TMPRSS2 and ERG gene fusion represses prostate tumor growth.
P2860
Q24628320-C9E96681-7C14-4A60-A850-3BA655F0A5FDQ33717554-F974617B-C20C-408E-9FD1-EF2B5A6F252BQ34053649-3E2493E3-1695-4A4E-ACD0-79619563F8B5Q34394131-77F68B0A-5774-43D1-9BB6-AB5C407CC186Q34459196-A611C16F-63C4-41B8-BB63-F7CF19E3005CQ35066396-234E2281-1D91-4019-960B-D92EAB0B8D33Q35552861-423FD258-5A80-45E4-8125-AACC7A2CCC34Q36031605-211AAF0A-721F-41C7-8694-5F5666F525E0Q36275422-86604ED3-E952-421C-B6E0-7098E1CAFD1EQ36342812-3EA6598C-8ECA-4806-AA9F-FA963F272E0FQ36594943-CFE318FB-51A9-40A6-8824-97A2012AB68AQ36836841-6C62C9D5-2F22-4AE7-ADEB-D979FD9D957BQ37210876-AFB5C17C-0A9A-4EE4-9B9B-EEFFB59858B5Q37418731-3D2B811F-DF1C-499F-8BA9-A9CA40CD7427Q38068802-7A3AD900-0A36-43E5-B1DB-1FEA3D9C5752Q38807563-6125B4FB-AD0D-4A74-A6DD-32711DE140D0Q38969070-4CF46D3E-F8EC-4DD1-94DD-CFEC640134E3
P2860
Pharmacokinetics of Py-Im polyamides depend on architecture: cyclic versus linear.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Pharmacokinetics of Py-Im polyamides depend on architecture: cyclic versus linear.
@ast
Pharmacokinetics of Py-Im polyamides depend on architecture: cyclic versus linear.
@en
type
label
Pharmacokinetics of Py-Im polyamides depend on architecture: cyclic versus linear.
@ast
Pharmacokinetics of Py-Im polyamides depend on architecture: cyclic versus linear.
@en
prefLabel
Pharmacokinetics of Py-Im polyamides depend on architecture: cyclic versus linear.
@ast
Pharmacokinetics of Py-Im polyamides depend on architecture: cyclic versus linear.
@en
P2093
P2860
P356
P1476
Pharmacokinetics of Py-Im polyamides depend on architecture: cyclic versus linear.
@en
P2093
Amanda E Hargrove
Jevgenij A Raskatov
P2860
P304
P356
10.1021/JA302588V
P407
P50
P577
2012-04-24T00:00:00Z